Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation
Phytotherapy Research · 2026-01 · 40 (1) · 213-226
DOI: 10.1002/ptr.70118 ↗At a glance
Journal article in Phytotherapy Research, published online on 2025-11-18. Written by Chunru Shi and 10 co-authors. Institution: Senior Department of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laborato…. Major MEDLINE topics: Macrophages, Monoterpenes, Glucosides, Diabetic Nephropathies. Cited 4 times so far (Crossref); 43 references. Funded by: National Natural Science Foundation of China, the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.
Abstract (original language)
Paeoniflorin (PF), a bioactive compound from Paeonia lactiflora , exhibits anti‐inflammatory and immunomodulatory effects. Macrophage‐driven inflammation is a key contributor to diabetic kidney disease (DKD). This study aimed to determine whether PF mitigates DKD by regulating macrophage polarization. The db/db mice were treated orally with PF (50 or 100 mg/kg/day) for 10 weeks. Renal function, histopathology, and macrophage infiltration were assessed. In vitro, RAW264.7 macrophages were exposed to high glucose. Network pharmacology, molecular docking, cellular thermal shift assays (CETSA), and HIF‐1α siRNA knockdown were used to investigate mechanistic targets. PF improved renal function, reduced albuminuria, and attenuated glomerular injury. It decreased CD68 + macrophage infiltration and inhibited M1 polarization, lowering TNF‐α and iNOS expression. PF directly bound and stabilized HIF‐1α, while HIF‐1α knockdown abolished PF's anti‐inflammatory effects. PF reduced HIF‐1α protein expression without affecting mRNA expression, indicating post‐transcriptional regulation. PF protects against DKD by inhibiting HIF‐1α–mediated M1 macrophage polarization, revealing a novel mechanism to modulate macrophage‐driven renal inflammation and supporting PF as a potential therapeutic agent for DKD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Senior Department of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western D…
- The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
- College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID profiles: Chunru Shi, Guosen He
Funding
- National Natural Science Foundation of China
- the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Cite
APA
Shi, C., Li, R., Deng, L., Pan, D., Fu, Z., He, G., Qu, Y., Liu, R., Wang, X., Chen, X., & Hong, Q. (2026). Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation. Phytotherapy Research, 40(1), 213-226. https://doi.org/10.1002/ptr.70118
Vancouver
Shi C, Li R, Deng L, Pan D, Fu Z, He G, et al. Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation. Phytotherapy Research. 2026;40(1):213-226. doi:10.1002/ptr.70118
BibTeX
@article{Shi2026,
author = {Shi, Chunru and Li, Run and Deng, Lingchen and Pan, Dan and Fu, Zhangning and He, Guosen and Qu, Yilun and Liu, Ran and Wang, Xu and Chen, Xiangmei and Hong, Quan},
title = {Paeoniflorin Attenuates the Progression of Diabetic Kidney Disease by Regulating Macrophage Differentiation},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {1},
pages = {213--226},
doi = {10.1002/ptr.70118}
}
EUVIMED